The APOBR Knockout A-549 Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout population derived from A-549 human lung adenocarcinoma cells, providing a loss-of-function model for the APOBR gene. This heterogeneous pool of gene disruptions offers a robust system for studying APOBR-mediated lipid metabolism without clonal selection bias.
A-549 cells are adherent epithelial cells isolated from the lung carcinoma tissue of a 58-year-old male, widely employed as a model for human alveolar type II epithelium. They retain key features of pulmonary epithelial differentiation and are extensively utilized in cancer biology, drug transporter studies, and metabolic research. Their capacity to acquire macrophage-like properties under certain stimuli makes them a versatile platform for investigating lipid metabolism and receptor function in a lung cancer context.
APOBR encodes a macrophage receptor that specifically binds VLDL and triglyceride-rich lipoproteins, mediating their internalization through clathrin-dependent endocytosis. This process relies on interactions with apolipoprotein E (apoE), LDL receptor-related protein (LRP), and the adaptor protein disabled-2 (DAB2). Transcriptional regulation of APOBR is driven by peroxisome proliferator-activated receptor gamma (PPAR??) and liver X receptor (LXR), with further induction by tumor necrosis factor-alpha (TNF-??) and interleukin-1 beta (IL-1??). Downstream, APOBR-mediated lipid uptake promotes triglyceride accumulation and foam cell formation, while simultaneously activating mitogen-activated protein kinase (MAPK) signaling and nuclear factor kappa-B (NF-??B) pathways. This positions APOBR within a broader network including VLDL receptor, LRP1, lipoprotein lipase (LPL), and CD36, integrating lipid transport with inflammatory cascades.
In A-549 cells, APOBR knockout is anticipated to disrupt VLDL internalization and reduce lipid droplet formation, attenuating foam cell-like phenotypes that can emerge under lipotoxic conditions. This model enables dissection of how triglyceride metabolism couples with epithelial-mesenchymal plasticity, inflammatory cytokine release, and oncogenic signaling in the lung tumor microenvironment, exploiting the A-549 capacity to adopt macrophage-like features.
These polyclonal knockout cells are ideally suited for VLDL uptake assays with fluorescently labeled lipoproteins, Oil Red O staining for neutral lipid accumulation, and triglyceride quantification via enzymatic kits. Protein-level analysis by western blotting for APOBR, phospho-MAPK, and NF-??B subunits can delineate signaling alterations, while RT-qPCR confirms gene expression changes. Flow cytometric lipid content measurement with Nile Red provides population-level insights. The model is applicable to macrophage differentiation assays and cytokine profiling to explore lipid-inflammation crosstalk. As such, the cells support diverse investigations in atherosclerosis, type 2 diabetes, obesity, and cancer metabolism. For additional details or custom cell engineering services, please contact Ascent Research.
